Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.

6 May 2010

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Researchers at Johns Hopkins have discovered that a compound in dark chocolate may protect the brain after a stroke by increasing cellular signals already known to shield nerve cells from damage.

6 May 2010

Scientists use specialized fluorescent protein to study nerve cell activity

Electrical currents are invisible to the naked eye - at least they are when they flow through metal cables. In nerve cells, however, scientists are able to make electrical signals visible. Working with fellow experts from Switzerland and Japan, scientists from the Max Planck Institute for Medical Research in Heidelberg successfully used a specialized fluorescent protein to visualize electrical activity in neurons of living mice.

6 May 2010

Spouses of dementia sufferers at higher risk of developing dementia

Older married adults whose spouse has dementia are at significantly higher risk for developing dementia themselves, compared to similar older married adults whose spouse never develops dementia. This is the key finding of a study published today in the Journal of the American Geriatrics Society.

5 May 2010

Principals of StemTroniX, Power3 Medical Products file patent application

StemTroniX, Inc., a Texas corporation, and Power3 Medical Products, Inc. announced today that a joint provisional patent application entitled, "Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy" has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

Research analyzes clinical connection of NPH to AD

Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Living with a dementia sufferer may affect spouse

In a new study researchers have revealed that partners of patients suffering from dementia or degeneration of memory and other mental faculties are six times more likely to develop the condition themselves.

4 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

Hartford Foundation awards $800,000 grant for training in geriatric social work

The prestigious Hartford Doctoral Fellows and Hartford Faculty Scholars programs have awarded $800,000 in combined new grants to ten researchers in the field of geriatric social work.

4 May 2010

New study shows people with BAV more likely to have brain aneurysms

A new study shows that people with a common heart defect may also be more likely to have brain aneurysms. The study is published in the May 4, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

4 May 2010

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

UCSF researchers have created the first transgenic mouse to display the earliest signs of Parkinson's disease using the genetic mutation that is known to accompany human forms of the disease.

4 May 2010

Algal DHA improves memory function in healthy aging adults: MIDAS

The Memory Improvement with Docosahexaenoic acid Study published online this week in Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that algal DHA improved memory function in healthy aging adults, providing a benefit roughly equivalent to having the learning and memory skills of someone three years younger.

4 May 2010

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Lung researchers at Johns Hopkins have identified a possible protein trigger responsible for sarcoidosis, a potentially fatal inflammatory disease marked by tiny clumps of inflammatory cells that each year leave deep, grainy scars on the lungs, lymph nodes, skin and almost all major organs in hundreds of thousands of Americans.

4 May 2010

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

New tool may help neurologists predict candidates for organ donation

A new tool may help neurologists predict which coma patients may be candidates for organ donation, according to a study published in the April 27, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

3 May 2010

Researchers use healthy person's complete genome sequence to predict risk for dozens of diseases

For the first time, researchers have used a healthy person's complete genome sequence to predict his risk for dozens of diseases and how he will respond to several common medications. The risk analysis, from the Stanford University School of Medicine, also incorporates more-traditional information such as a patient's age and gender and other clinical measurements.

30 Apr 2010

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

According to the Alzheimer's Association, over 5 million Americans are afflicted with Alzheimer's disease. While its cause is controversial, many people believe a correlation exists with toxin accumulation. Until recently, chelation, an invasive, drug-based toxin removal therapy, has been patients' primary option.

30 Apr 2010

Alzheimer's Disease News and Research

Further Reading

RayBiotech announces biomarker grant winners

GENFIT announces milestone as compound developed in partnership enters the clinic

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Scientists use specialized fluorescent protein to study nerve cell activity

Spouses of dementia sufferers at higher risk of developing dementia

Principals of StemTroniX, Power3 Medical Products file patent application

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Research analyzes clinical connection of NPH to AD

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Living with a dementia sufferer may affect spouse

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Hartford Foundation awards $800,000 grant for training in geriatric social work

New study shows people with BAV more likely to have brain aneurysms

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

Algal DHA improves memory function in healthy aging adults: MIDAS

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

New tool may help neurologists predict candidates for organ donation

Researchers use healthy person's complete genome sequence to predict risk for dozens of diseases

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

Aneuro: A Year of Neuroscience in Review eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News